Result of General Meeting November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage...

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with...

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 After Only Two Infusions and Two...

Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer 25 May 2018 Midatech Pharma PLC(“Midatech”, “Company” or “Group”) Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer Midatech Pharma (AIM:...